Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Post by lscfaon Feb 01, 2023 10:28am
417 Views
Post# 35259325

Co. update

Co. update

Steep decline in Q4 margin or was Q1,Q2, Q3 margins overstated?

 

 

Devices

 

 

 

Qtr ending

Deployed

Revenue

Gross Profit

Margin

 

 

 

 

 

Q4 22 (est)

420

1,208,861

132,052

10.9%

Q3 22

166

572,228

215,961

37.7%

Q2 22

53

176,175

56,874

32.3%

Q1 22

53

42,736

15,113

35.4%

 

 

2,000,000

420,000

21.0%

 

<< Previous
Bullboard Posts
Next >>